Connect with us

National

Ugandan president signs anti-gay bill into law

Yoweri Museveni was in an ‘upbeat mood’

Published

on

Yoweri Museveni, Uganda, gay news, Washington Blade

Uganda President Yoweri Museveni (Photo by the U.K. Department for International Development; courtesy Wikimedia Commons).

Ugandan President Yoweri Museveni on Monday signed a bill into law that imposes a life sentence upon anyone found guilty of repeated same-sex sexual acts.

“I have failed to understand that you can fail to be attracted to all these beautiful women and be attracted to a man,” Museveni told reporters as he signed the so-called Anti-Homosexuality Bill at his official residence in Entebbe, according to Agence France-Presse. “That is a really serious matter. There is something really wrong with you.”

The news agency reported Museveni described gays and lesbians as “mercenaries” who are actually “heterosexual people but because of money they say they are homosexuals.”

Museveni also said oral sex can cause worms, Hepatitis B and other sexually transmitted diseases.

“The mouth is for picking food, not for sex,” he said, according to Agence France-Presse. “We know the address for sex. That address (the mouth) is not for sex. The mouth is for eating not for sex. The mouth is engineered for kissing.”

Museveni signed the controversial measure less than a week after he rebuked President Obama’s criticism of him over the issue.

“Africans do not seek to impose their views on anybody,” said Museveni in a Feb. 18 statement. “We do not want anybody to impose their views on us. This very debate was provoked by Western groups who come to our schools and try to recruit children into homosexuality. It is better to limit the damage rather than exacerbate it.”

Museveni said he sought “scientific opinions” on whether people were “born homosexual.”

The Ugandan president in his statement specifically cited Robert F. Kennedy Center for Justice and Human Rights President Kerry Kennedy – with whom he met last month – for sending him information from U.S. scientists who said “there could be some indications that homosexuality could be congenital.” Museveni said scientists from the Ugandan Ministry of Health and two other agencies came to a “unanimous conclusion” that “homosexuality, contrary to my earlier thinking, was behavioral and not genetic.”

“What I want them to clarify is whether a combination of genes can cause anybody to be homosexual,” added the Ugandan president in his Feb. 18 statement. “Then my task will be finished and I will sign the bill.”

Ofwondo Opondo, a spokesperson for the Ugandan government, noted on Twitter that Arizona lawmakers last week approved a bill that would allow businesses to deny services to gays and lesbians based on their religious beliefs.

“What is [President] Obama saying to Arizona state law just passed to deny gays services on religious grounds,” said Opondo.

Frank Mugisha, executive director of Sexual Minorities Uganda, a Ugandan LGBT advocacy group, blasted Museveni.

“President Museveni’s scientific inquiry is a smokescreen for what is truly going on: political homophobia at its worst,” Mugisha told the Washington Blade. “Last month the President said he would not sign this fascist bill. But now, it seems he has sold us out for the votes of his party. It is politics – plain and simple – all at the expense of LGBTI Ugandans.”

U.N. High Commissioner for Human Rights Navi Pillay is among those who also criticized the Ugandan president for signing the bill.

“This law violates a host of fundamental human rights, including the right to freedom from discrimination, to privacy, freedom of association, peaceful assembly, opinion and expression and equality before the law – all of which are enshrined in Uganda’s own constitution and in the international treaties it has ratified,” said Pillay.

Uganda is among the 70 countries in which homosexuality remains criminalized.

U.S. Sen. Jim Inhofe (R-Okla.), who met with Museveni last month during a trip to Uganda with four other American lawmakers, is among those who have urged the Ugandan president not to sign the Anti-Homosexuality Bill into law.

“I certainly disagree with the controversial legislation that Uganda may enact in the coming days,” the Oklahoma Republican told the Washington Blade last week. “As I’ve said before, it is my hope that the country will abandon this unjust and harsh legislation.”

The Center for Constitutional Rights in March 2012 filed a federal lawsuit against Scott Lively on behalf of Sexual Minorities Uganda, a Ugandan LGBT rights group, that accuses the evangelical Christian of exploiting homophobic attitudes in the East African country and encouraging lawmakers to approve the Anti-Homosexuality Bill. Judge Michael A. Posner of the U.S. District Court for the District of Massachusetts last August ruled the lawsuit can proceed.

Scott Lively, anti-gay, gay news, Washington Blade

Anti-gay activist Scott Lively spoke at the Coalition for Family Values press conference at the National Press Club on Feb. 21. (Washington Blade photo by Michael Key)

Lively described the Center for Constitutional Rights as a “Marxist law firm from New York City” during a Feb. 21 press conference at the National Press Club in downtown Washington where he and other anti-gay advocates announced the creation of a new organization designed to combat the global LGBT rights movement.

“The purpose of the lawsuit is to shut me up because I speak very articulately about the homosexual issue from a pro-family perspective,” said Lively in response to the Blade’s question about the lawsuit and whether his new group will encourage additional anti-LGBT violence and discrimination in Uganda and other countries.

Lively categorized the Anti-Homosexuality Bill to the Blade as “overly harsh on its face, but this is typical of African criminal law across the continent.”

“Poor countries with limited criminal justice systems tend to rely on the harshness of the letter of the law to be a deterrent to criminals,” he said on Monday. “In practice, the sentencing is usually pretty lenient. Kenya, for example, has the death penalty for burglary, but burglars are definitely not being executed there.”

Lively added he has “explained this phenomenon” to more than two dozen journalists at “top media outlets that have interviewed me over the past couple of years, but none have included this perspective in their stories.”

“I guess it would undermine their efforts to bolster the ‘gay’ cause,” he told the Blade.

The Washington Blade will have more information on this story as it becomes available.

Advertisement
FUND LGBTQ JOURNALISM
SIGN UP FOR E-BLAST

National

FDA approves new twice-yearly HIV prevention drug

Experts say success could inhibit development of HIV vaccine

Published

on

New HIV prevention drug Lenacapavir replaces oral medicines with twice-yearly injections. (Photo by fet/Bigstock)

The U.S. Food and Drug Administration (FDA) on June 18 approved a newly developed HIV/AIDS prevention drug that only needs to be taken by injection once every six months.

The new drug, lenacapavir, which is being sold under the brand name of Yeztugo by the pharmaceutical company Gilead Sciences that developed it, is being hailed by some AIDS activists as a major advancement in the years-long effort to end the HIV/AIDS epidemic in the U.S. and worldwide.

Although HIV prevention drugs, known as pre-exposure prophylaxis medication or PrEP, have been available since 2012, they initially required taking one or more daily pills. More recently, another injectable PrEP drug was developed that required being administered once every two months.

Experts familiar with the PrEP programs noted that while earlier drugs were highly effective in preventing HIV infection – most were 99 percent effective – they could not be effective if those at risk for HIV who were on the drugs did not adhere to taking their daily pills or injections every two months. Experts also point out that large numbers of people at risk for HIV, especially members of minority communities, are not on PrEP and efforts to reach out to them should be expanded.

“Today marks a monumental advance in HIV prevention,” said Carl Schmid, executive director of the D.C.-based HIV + Hepatitis Policy Institute, in a statement released on the day the FDA announced its approval of lenacapavir.

“Congratulations to the many researchers who spent 19 years to get to today’s approval, backed up by the long-term investment needed to get the drug to market,” he said.

Schmid added, “Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections – if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.”

Schmid and others monitoring the nation’s HIV/AIDS programs have warned that proposed large scale cuts in the budget for the U.S. Centers for Disease Control and Prevention by the administration of President Donald Trump could seriously harm HIV prevention programs, including PrEP-related efforts.

“Dismantling these programs means that there will be a weakened public health infrastructure and much less HIV testing, which is needed before a person can take PrEP,” Schmid said in his statement.

“Private insurers and employers must also immediately cover Yeztugo as a required preventive service, which means that PrEP users should not face any cost-sharing or utilization management barriers,” he said.

In response to a request by the Washington Blade for comment,  a spokesperson for Gilead Sciences released a statement saying the annual list price per person using Yeztugo in the U.S. is $28,218. But the statement says the company is working to ensure that its HIV prevention medication is accessible to all who need it through broad coverage from health insurance companies and some of its own support programs.

“We’ve seen high insurance coverage for existing prevention options – for example, the vast majority of consumers have a $0 co-pay for Descovy for PrEP in the U.S. – and we are working to ensure broad coverage for lenacapavir [Yeztugo],” the statement says. It was referring to the earlier HIV prevention medication developed by Gilead Sciences, Descovy.

“Eligible insured people will get help with their copay,” the statement continues. “Gilead’s Advancing Access Copay Savings Program may reduce out-of-pocket costs to as little as zero dollars,” it says. “Then for people without insurance, lenacapavir may be available free of charge for those who are eligible, through Gilead’s Advancing Access Patient Assistance Program.”

Gilead Sciences has announced that in the two final trial tests for Yeztugo, which it describes as “the most intentionally inclusive HIV prevention clinical trial programs ever designed,” 99.9 percent of participants who received Yeztugo remained negative. Time magazine reports that among those who remained HIV negative at a rate of 100 percent were men who have sex with men. 

Time also reports that some HIV/AIDS researchers believe the success of the HIV prevention drugs like Gilead’s Yeztugo could complicate the so-far unsuccessful efforts to develop an effective HIV vaccine. 

To be able to test a potential vaccine two groups of test subjects must be used, one that receives the test vaccine and the other that receives a placebo with no drug in it. 

With highly effective HIV prevention drugs now available, it could be ethically difficult to ask a test group to take a placebo and continue to be at risk for HIV, according to some researchers. 

“This might take a bit of the wind out of the sails of vaccine research, because there is something so effective in preventing HIV infection,”  Time quoted Dr. David Ho, a professor of microbiology, immunology, and medicine at New York’s Columbia University as saying.

Continue Reading

National

Activists rally in response to Supreme Court ruling

‘We won’t bow to hatred: we outlive it’

Published

on

Hope Giselle-Godsey speaks at a rally for trans rights at the Lutheran Church of the Reformation on Wednesday, June 18. (Washington Blade photo by Michael Key)

Politicians, LGBTQ activists, and allies gathered at the Lutheran Church of the Reformation in the Capitol Hill neighborhood of Washington, D.C. on Wednesday following the ruling by the United States Supreme Court in the case of U.S. v. Skrmetti. The Supreme Court upheld a Tennessee ban on gender-affirming healthcare for transgender adolescents in a 6-3 decision.

A rally outside the U.S. Supreme Court was called for by the American Civil Liberties Union, Lambda Legal and other organizations following the high court ruling on Wednesday. However, due to a thunderstorm and flood watch, the scores of activists who were to attend the rally were directed to a Lutheran church down the street from the court. Undeterred, activists and community leaders were joined by U.S. Senators Ed Markey (D-Mass.) and Jeff Merkley (D-Ore.) for an indoor rally at the church.

“We know that freedom is not inevitable,” Markey told the crowd. “It is fought for by people who said ‘no’ in the face of health cuts, ‘no’ in the face of discrimination, ‘no’ in the face of invasive laws that ban life-saving and life-affirming healthcare and ‘no’ to this anti-justice, anti-freedom agenda.”

Also speaking at the rally was Deirdre Schifeling, chief political advocacy officer of the National ACLU.

“We believe transgender rights matter,” Schifeling stated. “Transgender kids matter and deserve love, support and the freedom to shape their own futures. I am still processing how the Supreme Court could disagree with such an obvious truth.”

“Today’s ruling shows us that unfortunately these attacks on our freedom will not end here,” Schifeling continued. “The Trump administration and extremist politicians across the country are continuing to target our right — our human right — to control our own bodies.”

“If politicians think that we are going to sit back and be defeated, that we are going to let them strip our rights and freedoms away without a fight, they’ve got another think coming,” Schifeling said. “We will never back down. We will never back down or give up. We will organize, we will mobilize and we will fight to protect trans rights in our communities, in our legislatures, in our elections, and in court rooms across the country.”

(Washington Blade photo by Michael Key)

“Today, the highest court in this land decided that the bodily autonomy of trans youth, specifically trans youth of Tennessee and states with bans harming youth across the country do not matter,” said trans advocate Hope Giselle-Godsey.

“The opponents of trans equality think that today is a victory, but history will remember it as a moment that sharpened us and not silenced us,” Giselle-Godsey continued.

“So yes, today we grieve for the people in those states where those bans exist, but we grieve in motion,” Giselle-Godsey said. “To the system that thinks that it won today, just like every other time before: you will lose again. Because we won’t bow to hatred: we outlive it. We out-organize it. We out-love it. We are still here and we are not finished yet.”

‘As we proceed, the most important pressure here is from the people,’ U.S. Sen. Jeff Merkley (D-Ore.) tells a crowd of trans rights activists at the Lutheran Church of the Reformation on Wednesday, June 18. (Washington Blade photo by Michael Key)
Continue Reading

U.S. Supreme Court

Lawyers who fought gender affirming care ban at the Supreme Court remain optimistic

Wednesday’s decision, while disappointing, leaves room for more legal challenges

Published

on

Chase Strangio, deputy director for transgender justice at the ACLU’s LGBTQ & HIV Project
Chase Strangio co-director of the ACLU's LGBT & HIV Project and nationally recognized expert on transgender rights (Screen shot: YouTube)

Following the U.S. Supreme Court’s ruling on Wednesday upholding Tennessee’s ban on medical care for transgender minors, several of the plaintiffs’ attorneys expressed disappointment with the outcome but stressed that the fight was not over.

While the decision in U.S. v. Skrmetti will shield Tennessee and more than 20 other states from litigation challenging their anti-trans healthcare restrictions, the majority decision was not so broadly written that opportunities to fight for expanded rights and protections — or to push back against the Trump-Vance administration’s discriminatory policies — were extinguished, they said.

Addressing reporters during a press call hours after the decision was released were Chase Strangio, co-director of the ACLU’s LGBTQ & HIV Project, Karen Loewy, director of constitutional law practice at Lambda Legal, and Lucas Cameron-Vaughn, senior staff attorney at the ACLU of Tennessee.

On the one hand, the lawyers were adamant that the conservative justices in the 6-3 majority opinion “got this completely wrong,” as Cameron-Vaughn said, because Tennessee’s law is “clearly a sex based classification and transgender based classification” on its face.

At the same time, he said “the fact that it’s a narrow ruling means that we will continue to fight and stand with trans people and their families in Tennessee with all the tools at our disposal to continue to stand against the assault from the government.”

Explained Strangio, “The court did not rule on whether or not transgender status independently warrants the type of heightened scrutiny that sex based classifications also trigger,” meaning that “lower court decisions — for example, in the 9th and the 4th Circuit that have already recognized that transgender status triggers this type of heightened scrutiny — will remain good law, and that government discrimination targeting transgender people, either through facial classifications or invidious discrimination, are both contexts in which the [Supreme] Court has today explicitly left open for heightened scrutiny.”

“The most immediate effect is on our clients and other young, young transgender people in Tennessee and across the country who need medical care that the government has stepped in to ban,” added Strangio, who is the first transgender attorney to argue before the Supreme Court. “And for them, we are devastated, and we know that we will continue fighting so that government discrimination against transgender people will end.”

“This is a setback in many ways,” he said, “but we continue onward in the fight and we can, you know, hold simultaneously, both the pain of this decision and all of the possibilities of the future we’re building.”

Responding to a question from the Washington Blade about whether the justices considered the potential harms of cutting off access to treatments for young people who have begun to medically transition, Strangio said he and his co-counsel stressed the issue in briefs and during oral argument.

He continued, “I think one of the frustrating things about the type of deference that this court found would apply here” as opposed to a more heightened level of scrutiny “is that they don’t really look at the underlying evidence, and so they can just sort of defer broadly and uncritically to state legislatures or legislatures more more generally.”

Strangio noted that while the dissenting opinions from the liberal justices, particularly Sonia Sotomayor’s, addressed harms related to the sudden loss of access to treatments for transgender youth, “that did not figure in in the majority opinions, in the ways that we all wished that it would have.”

“And we know how devastating it is for people to lose access to medically necessary care,” he said.

Responding to the same question, Loewy said “I would just lift up Justice Sotomayor’s dissent in as much as her questioning of Tennessee’s attorneys during argument was a recognition of the real harms to our actual clients. And her dissent really talks about what it meant before our clients had access to the gender affirming medical care that they needed, and the real harm of that now being unavailable to them.”

“So, there was definitely some recognition during the discussion, during argument, of what this really means for trans young people,” Loewy said. “And you know, it was clearly not part of the calculus that the majority was willing to really consider.”

Continue Reading

Popular